In A New Study RotarixTM Offers 96% Protection Against Severe Rotavirus Gastroenteritis And Prevents 100% Of Rotavirus-associated Hospitalisations

Editorial Office

Abstract


Data from a recent study announced at ESPID (European
Society for Paediatric Infectious Diseases) shows that ROTARIXTM, the first oral rotavirus vaccine available to children in Europe, protects against 96% of severe rotavirus gastroenteritis (RVGE) cases and prevents 100% of hospitalisations due to rotavirusinduced gastroenteritis in a European setting.1

Full Text: PDF


This journal is hosted by: OpenJournals Publishing. This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.5 South Africa License